Browsing Category
Investing
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II
Overview
Cardiol Therapeutics (NASDAQ:CRDL,TSX:CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The…
Fund Managers: “Highly Constructive” on Uranium Price, Stocks We’re
Keith Watson and Rob Crayfourd, co-fund managers at the Geiger Counter Fund, shared their outlook on uranium supply, demand and prices, plus which companies they think have the most potential moving forward. While acknowledging the…
190 Metre Antimony Copper Intercept at Bulla Park
A former mining opponent, a brilliant materials engineer and a respected leader in the male-dominated offshore drilling space are among the winners of Australia’s 2024 Women in Resources National Awards announced in the nation’s capital…
Operations Update | INN
Having long focused on green hydrogen projects, CHARBONE is now exploring to deepen its involvement in white hydrogen, to complement its future network of production facilities. By leveraging its extensive expertise in the hydrogen…
Offer Booklet Non-Renounceable Rights Issue Offer
The directors (Directors) of Energy Technologies Limited (ASX: EGY) ACN 002 679 469 (Company) are pleased to offer you the opportunity to participate in a non-renounceable rights issue on the basis of 1 new fully paid ordinary share in…
Lithium Universe Limited (ASX: LU7) – Trading Halt
Melbourne, Australia (ABN Newswire) - Lithium Universe Limited (ASX:LU7) (OTCMKTS:ESMAF) is pleased to announce a project update of the Becancour Lithium Refinery Project. The project is advancing well and remains on track. Key…
Update on the ASX Listing
Highlights:An initial volume of 88m3 of concentrated eluate, which is the lithium carbonate equivalent (LCE) of approx. one tonne, has been produced from the Company´s DLE pilot plant in Copiapó, Chile over an operating period of 384…
FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer
Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to Amplia’s Focal Adhesion Kinase inhibitor,…
Low Cost Technology to be Trialed in DLE Pilot Plant Conversion Stage,
Highlights:An initial volume of 88m3 of concentrated eluate, which is the lithium carbonate equivalent (LCE) of approx. one tonne, has been produced from the Company´s DLE pilot plant in Copiapó, Chile over an operating period of 384…
Sarama Completes Issue of Shares for Debt and ASX Cleansing Notice
Sarama Resources Ltd. (“Sarama” or the “Company”) (ASX:SRR, TSX- V:SWA) is pleased to report that on 18 September 2024, it had completed the issue of shares in part settlement of deferred executive salaries and director fees (the…